TN2019000153A1 - Magl inhibitors - Google Patents
Magl inhibitorsInfo
- Publication number
- TN2019000153A1 TN2019000153A1 TNP/2019/000153A TN2019000153A TN2019000153A1 TN 2019000153 A1 TN2019000153 A1 TN 2019000153A1 TN 2019000153 A TN2019000153 A TN 2019000153A TN 2019000153 A1 TN2019000153 A1 TN 2019000153A1
- Authority
- TN
- Tunisia
- Prior art keywords
- magl inhibitors
- compositions
- magl
- useful
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423099P | 2016-11-16 | 2016-11-16 | |
| PCT/US2017/061868 WO2018093947A1 (en) | 2016-11-16 | 2017-11-15 | Magl inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2019000153A1 true TN2019000153A1 (en) | 2020-10-05 |
Family
ID=62106678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2019/000153A TN2019000153A1 (en) | 2016-11-16 | 2017-11-15 | Magl inhibitors |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10093635B2 (https=) |
| EP (1) | EP3541821A4 (https=) |
| JP (1) | JP7042547B2 (https=) |
| KR (1) | KR20190077544A (https=) |
| CN (1) | CN110267963B (https=) |
| AR (1) | AR110089A1 (https=) |
| AU (1) | AU2017361251B2 (https=) |
| BR (1) | BR112019009994A2 (https=) |
| CA (1) | CA3043615A1 (https=) |
| CL (1) | CL2019001339A1 (https=) |
| CO (1) | CO2019005059A2 (https=) |
| CR (1) | CR20190241A (https=) |
| DO (1) | DOP2019000122A (https=) |
| EA (1) | EA038090B1 (https=) |
| EC (1) | ECSP19035077A (https=) |
| GE (2) | GEP20237470B (https=) |
| IL (1) | IL266523B (https=) |
| JO (1) | JOP20190106A1 (https=) |
| MA (1) | MA46857A (https=) |
| MX (1) | MX391117B (https=) |
| NI (1) | NI201900051A (https=) |
| PE (1) | PE20191144A1 (https=) |
| PH (1) | PH12019501097A1 (https=) |
| RU (1) | RU2754536C1 (https=) |
| TN (1) | TN2019000153A1 (https=) |
| TW (1) | TWI756299B (https=) |
| UA (1) | UA124542C2 (https=) |
| WO (1) | WO2018093947A1 (https=) |
| ZA (1) | ZA201903100B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141702A1 (es) | 2012-01-06 | 2014-11-19 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos |
| CN113413387A (zh) | 2015-05-11 | 2021-09-21 | H.隆德贝克有限公司 | 治疗炎症或神经性疼痛的方法 |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| UA124884C2 (uk) | 2016-11-16 | 2021-12-08 | Лундбек Ла Джолла Ресеарч Центер, Інк. | Фармацевтичні склади |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MA46866B1 (fr) | 2016-11-16 | 2021-11-30 | H Lundbeck As | Une forme cristalline d'un inhibiteur de magl |
| DK3630744T3 (da) | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| JP7257387B2 (ja) | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| GEP20227443B (en) * | 2018-05-15 | 2022-11-25 | H Lundbeck As | Magl inhibitors |
| CA3125636A1 (en) * | 2019-01-25 | 2020-07-30 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| KR20220101095A (ko) * | 2019-11-15 | 2022-07-19 | 하. 룬드벡 아크티에셀스카브 | Magl 억제제의 결정형 |
| IT202000007150A1 (it) * | 2020-04-03 | 2021-10-03 | Univ Pisa | Inibitori di monoacilglicerolo lipasi (magl) |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (https=) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| EP0619804B1 (en) | 1991-11-27 | 1996-05-22 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| DE69408873T2 (de) | 1993-12-22 | 1998-07-09 | Shell Int Research | Verfahren zur herstellung von carbamaten |
| WO1997018196A1 (en) | 1995-11-15 | 1997-05-22 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| AU7855900A (en) | 1999-10-04 | 2001-05-10 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying rna binding compounds |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
| BRPI0507499A (pt) | 2004-02-18 | 2007-07-24 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 |
| US7786113B2 (en) | 2004-12-23 | 2010-08-31 | Hoffman-La Roche Inc. | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| WO2007052023A2 (en) | 2005-11-05 | 2007-05-10 | Astrazeneca Ab | Novel compounds |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| WO2008078091A1 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP2011528368A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用 |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| WO2010111050A1 (en) | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| US8455476B2 (en) | 2009-04-22 | 2013-06-04 | Janssen Pharmaceutica, Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| ES2433235T3 (es) | 2009-11-03 | 2013-12-10 | Bayer Intellectual Property Gmbh | Fluorouretanos como aditivos en una formulación de fotopolímero |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| PE20141702A1 (es) | 2012-01-06 | 2014-11-19 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos |
| NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| CA2866302A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| JP2014005245A (ja) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| JP6647592B2 (ja) * | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| US10570146B2 (en) * | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| JP2018513119A (ja) * | 2015-03-18 | 2018-05-24 | アビデ セラピューティクス，インク． | ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法 |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-06-16 JO JOP/2019/0106A patent/JOP20190106A1/ar unknown
- 2017-11-15 MA MA046857A patent/MA46857A/fr unknown
- 2017-11-15 CN CN201780083663.6A patent/CN110267963B/zh not_active Expired - Fee Related
- 2017-11-15 UA UAA201905620A patent/UA124542C2/uk unknown
- 2017-11-15 US US15/814,322 patent/US10093635B2/en active Active
- 2017-11-15 WO PCT/US2017/061868 patent/WO2018093947A1/en not_active Ceased
- 2017-11-15 AU AU2017361251A patent/AU2017361251B2/en not_active Ceased
- 2017-11-15 GE GEAP201715088A patent/GEP20237470B/en unknown
- 2017-11-15 CR CR20190241A patent/CR20190241A/es unknown
- 2017-11-15 GE GEAP202215088A patent/GEAP202215088A/en unknown
- 2017-11-15 JP JP2019523587A patent/JP7042547B2/ja not_active Expired - Fee Related
- 2017-11-15 RU RU2019116512A patent/RU2754536C1/ru active
- 2017-11-15 CA CA3043615A patent/CA3043615A1/en active Pending
- 2017-11-15 BR BR112019009994A patent/BR112019009994A2/pt not_active IP Right Cessation
- 2017-11-15 EA EA201991073A patent/EA038090B1/ru unknown
- 2017-11-15 EP EP17871753.4A patent/EP3541821A4/en not_active Withdrawn
- 2017-11-15 AR ARP170103184A patent/AR110089A1/es not_active Application Discontinuation
- 2017-11-15 KR KR1020197016924A patent/KR20190077544A/ko not_active Abandoned
- 2017-11-15 PE PE2019001014A patent/PE20191144A1/es unknown
- 2017-11-15 IL IL266523A patent/IL266523B/en unknown
- 2017-11-15 MX MX2019005776A patent/MX391117B/es unknown
- 2017-11-15 TN TNP/2019/000153A patent/TN2019000153A1/en unknown
- 2017-11-16 TW TW106139775A patent/TWI756299B/zh not_active IP Right Cessation
-
2019
- 2019-05-16 EC ECSENADI201935077A patent/ECSP19035077A/es unknown
- 2019-05-16 DO DO2019000122A patent/DOP2019000122A/es unknown
- 2019-05-16 CL CL2019001339A patent/CL2019001339A1/es unknown
- 2019-05-16 PH PH12019501097A patent/PH12019501097A1/en unknown
- 2019-05-16 NI NI201900051A patent/NI201900051A/es unknown
- 2019-05-16 CO CONC2019/0005059A patent/CO2019005059A2/es unknown
- 2019-05-17 ZA ZA201903100A patent/ZA201903100B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551934A1 (en) | Magl inhibitors | |
| PH12019501097A1 (en) | Magl inhibitors | |
| PH12019501102A1 (en) | Magl inhibitors | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| PH12019501079A1 (en) | Magl inhibitors | |
| GB2541571A (en) | Pharmaceutical compositions | |
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2019014042A (es) | Inhibidores pirazolicos de magl. | |
| PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| NZ797704A (en) | Dual magl and faah inhibitors | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| PH12017500602A1 (en) | Methods for treating ocular conditions | |
| EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза |